Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results
-- Antimicrobial Drugs Advisory Committee of FDA scheduled for August 8, 2018 to review the Company's NDAs for omadacycline -- -- Omadacycline PDUFA action date scheduled for October 2018 -- -- Company on track for a first quarter 2019 omadacycline U.S …